Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Biofrontera (BFRIW) over the last 6 years, with Q3 2025 value amounting to $3.4 million.

  • Biofrontera's Cash & Equivalents rose 1782.76% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 1782.76%. This contributed to the annual value of $5.9 million for FY2024, which is 33968.73% up from last year.
  • Biofrontera's Cash & Equivalents amounted to $3.4 million in Q3 2025, which was up 1782.76% from $7.2 million recorded in Q2 2025.
  • Over the past 5 years, Biofrontera's Cash & Equivalents peaked at $31.9 million during Q2 2022, and registered a low of $1.3 million during Q1 2023.
  • In the last 5 years, Biofrontera's Cash & Equivalents had a median value of $4.1 million in 2024 and averaged $10.1 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 150361.31% in 2022, then plummeted by 9420.37% in 2023.
  • Quarter analysis of 5 years shows Biofrontera's Cash & Equivalents stood at $24.5 million in 2021, then fell by 29.89% to $17.2 million in 2022, then crashed by 92.2% to $1.3 million in 2023, then surged by 339.69% to $5.9 million in 2024, then plummeted by 42.13% to $3.4 million in 2025.
  • Its Cash & Equivalents stands at $3.4 million for Q3 2025, versus $7.2 million for Q2 2025 and $1.8 million for Q1 2025.